A novel approach to target inflammatory diseases

A novel approach to target inflammatory diseases

Inotrem is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.

Inotrem_Picto Trem 1

Inotrem identified the TREM-1 pathway as a key factor causing unbalanced inflammatory responses. The company focuses on the therapeutic tools derived from knowledge of the biology of TREM-1 pathway.

Inotrem_Picto Pipeline

Through its proprietary technology platform, Inotrem has developed the first-in-class clinical TREM-1 inhibitor, nangibotide (LR12), with applications in a number of indications such as septic shock or myocardial infarction.

Inotrem_Picto Trem 1

INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases.

Inotrem_Picto Pipeline

A first clinical trial to assess the safety, tolerability and pharmacokinetics of MOTREM in healthy volunteers is currently ongoing.

Events

France Biotech

February 19. 2019 in Paris. Martin Koch, COO of Inotrem, participates to “Market Access and Biotechnologies”, a panel discussion organized by France Biotech, France’s main

Read More »
Events

France Biotech

February 19. 2019 in Paris. Martin Koch, COO of Inotrem, participates to “Market Access and Biotechnologies”, a panel discussion organized by France Biotech, France’s main

Read More »